Analysts Offer Predictions for Cingulate FY2026 Earnings

Cingulate Inc. (NASDAQ:CING) – Research analysts at Zacks Research reduced their FY2026 EPS estimates for Cingulate in a research note issued to investors on Tuesday, May 19th. Zacks Research analyst J. Vandermosten now forecasts that the company will earn ($2.42) per share for the year, down from their previous estimate of ($1.43). The consensus estimate for Cingulate’s current full-year earnings is ($2.19) per share. Zacks Research also issued estimates for Cingulate’s FY2027 earnings at ($1.55) EPS.

Cingulate (NASDAQ:CING) last announced its earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.42).

A number of other research analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cingulate in a research note on Monday, April 20th. Wall Street Zen downgraded shares of Cingulate from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Roth Mkm reiterated a “buy” rating and set a $10.00 price objective on shares of Cingulate in a research note on Tuesday. Finally, Ascendiant Capital Markets reduced their price objective on shares of Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.50.

Cingulate Price Performance

NASDAQ CING opened at $4.74 on Friday. Cingulate has a 12 month low of $3.20 and a 12 month high of $11.89. The company has a market capitalization of $62.93 million, a price-to-earnings ratio of -1.12 and a beta of -0.81. The company’s fifty day moving average price is $6.04 and its two-hundred day moving average price is $5.32.

Institutional Trading of Cingulate

A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in shares of Cingulate during the first quarter worth $198,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Cingulate during the first quarter worth $116,000. Kestra Advisory Services LLC raised its holdings in shares of Cingulate by 14.8% during the first quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock worth $869,000 after purchasing an additional 18,000 shares during the period. XTX Topco Ltd acquired a new stake in shares of Cingulate during the fourth quarter worth $90,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Cingulate during the fourth quarter worth $66,000. 41.31% of the stock is owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.